Product Name: Lu AE58054
Chemical Name: 2-(6-fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
SMILES Code: FC1=CC2=C(C=C1)C(CCNCC3=CC=CC(OCC(F)(F)C(F)F)=C3)=CN2
CAS NO: 167074-97-7 Product: LY451395
Synonym: Idalopirdine; Lu AE 58054
Chemical Formula: C20H19F5N2O
Appearance: Solid powderWeb Site：Medchemexpress
Purity: 98% (this data is for the first batch)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 8211; 4 C for short term (days to weeks) or -20 C for long term (months to years).Dopamine beta)-hydroxylase inhibitors
Solubility: Soluble in DMSO, not in water
Background Description: Lu AE58054 (Iladopirdine) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia. It is in phase III PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/15719269
Related Posts
Product Name: Lu AE58054
Chemical Name: 2-(6-fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine
SMILES Code: FC1=CC2=C(C=C1)C(CCNCC3=CC=CC(OCC(F)(F)C(F)F)=C3)=CN2
CAS NO: 167074-97-7 Product: LY451395
Synonym: Idalopirdine; Lu AE 58054
Chemical Formula: C20H19F5N2O
Appearance: Solid powderWeb Site：Medchemexpress
Purity: 98% (this data is for the first batch)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 8211; 4 C for short term (days to weeks) or -20 C for long term (months to years).Dopamine beta)-hydroxylase inhibitors
Solubility: Soluble in DMSO, not in water
Background Description: Lu AE58054 (Iladopirdine) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer’s disease and schizophrenia. It is in phase III PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/15719269